Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijá leads to the loss of thrombin proteolytic activity.
Prothrombin Perijá is a dysprothrombin derived from a homozygous patient that manifests low thrombin activity upon activation in a one-stage assay. Purified prothrombin Perijá showed normal appearance on SDS-PAGE. and was cleaved normally to form alpha-thrombin by the prothrombinase complex. The activated form, thrombin Perijá, however, did not show any proteolytic activity towards native substrates, fibrinogen, protein C or various synthetic substrates for alpha-thrombin, but it was able to bind to antithrombin III, although the binding capacity was markedly reduced even in the presence of heparin. Thrombin Perijá showed full reactivity toward a small inhibitor, DFP, indicating that the molecular defect is in the substrate binding site in the thrombin molecule but not in the active site itself. By DNA sequence analysis of the patient prothrombin gene, we identified a G to C mutation at nucleotide 20016 in exon 14, which predicts a Gly-548 to Ala substitution in the prothrombin Perijá molecule. The structural modeling of thrombin Perijá suggests that Ala-548 is located close to the limb of the cavity wall of the substrate binding pocket, and that the methyl group blocks protrusion of the guanidino group of Arg into the cavity. This steric hindrance may well inhibit the access of Arg-containing substrates to the catalytic Ser-525 leading to the loss of proteolytic activity.
Sekine
Osamu
O
Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan.
Sugo
Teruko
T
Ebisawa
Kazuyoshi
K
Umeyama
Hideaki
H
Iwahana
Hiroyuki
H
Ruiz-Sáez
Arlette
A
de Bosch
Norma
N
Matsudai
Michio
M
D000409:Alanine / Q000737:chemistry; D019943:Amino Acid Substitution; D000990:Antithrombin III / Q000378:metabolism; D001120:Arginine / Q000737:chemistry / Q000031:analogs & derivatives; D001665:Binding Sites; D020134:Catalytic Domain; D003062:Codon / Q000235:genetics; D004252:DNA Mutational Analysis; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005091:Exons / Q000235:genetics; D005165:Factor V / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D005998:Glycine / Q000737:chemistry; D006801:Humans; D008958:Models, Molecular; D010875:Pipecolic Acids / Q000494:pharmacology; D018807:Polymorphism, Single-Stranded Conformational; D011487:Protein Conformation; D011516:Prothrombin / Q000737:chemistry* / Q000235:genetics; D012694:Serine / Q000737:chemistry; D013329:Structure-Activity Relationship; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism
D003062:Codon; D004791:Enzyme Inhibitors; D010875:Pipecolic Acids; D013449:Sulfonamides; C051338:prothrombin Perija; C022475:prothrombinase complex; D012694:Serine; D000990:Antithrombin III; D005165:Factor V; D011516:Prothrombin; D001120:Arginine; D013917:Thrombin; C464793:thrombin Perija; C027648:thrombin Quick; D015951:Factor Xa; C031942:argatroban; D000409:Alanine; D005998:Glycine